Search research articles
Contact Us
Filters
Showing results (81-90 of 706) with videos related to
Page
of 71
Sort By:
Expert Opinion on Emerging Drugs
|
April 12, 2015
Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention
Michael M Page, Gerald F Watts
Clinical and Translational Medicine
|
November 27, 2023
RNA interference therapy for targeting ANGPTL3 and atherogenic lipoproteins: Findings and implications of a recent phase I study
Gerald F Watts, Dick C Chan
Current Opinion in Endocrinology, Diabetes, and Obesity
|
September 2, 2024
Cardiometabolic risk factors in women: what's sauce for the goose is not sauce for the gander
Wann Jia Loh, Gerald F Watts
Current Atherosclerosis Reports
|
November 20, 2024
Inhibition of the ANGPTL3/8 Complex for the Prevention and Treatment of Atherosclerotic Cardiovascular Disease
Dick C Chan, Gerald F Watts
Current Opinion in Lipidology
|
February 19, 2024
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Dick C Chan, Gerald F Watts
Clinical Therapeutics
|
July 31, 2023
The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies
Dick C Chan, Gerald F Watts
Current Atherosclerosis Reports
|
February 26, 2025
Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?
Nick S R Lan, Gerald F Watts
The Medical Journal of Australia
|
February 5, 2013
Familial hypercholesterolaemia in Australia: new insights and developments
Ian R Hamilton-Craig, Gerald F Watts
Clinical Chemistry
|
January 8, 2021
Hypertriglyceridemia and Alzheimer Disease: Opening the Mind to New Therapeutic Opportunities
Gerald F Watts, John C L Mamo
Current Opinion in Lipidology
|
October 17, 2018
Writing on the wall for precision medicine in the prevention of atherosclerotic cardiovascular disease
Gerald F Watts, Eric S G Stroes
Page
of 71
Search research articles
Search
Showing results (81-90 of 706) with videos related to
Sort By:
Page
of 71
Expert Opinion on Emerging Drugs
|
April 12, 2015
Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention
Michael M Page, Gerald F Watts
Clinical and Translational Medicine
|
November 27, 2023
RNA interference therapy for targeting ANGPTL3 and atherogenic lipoproteins: Findings and implications of a recent phase I study
Gerald F Watts, Dick C Chan
Current Opinion in Endocrinology, Diabetes, and Obesity
|
September 2, 2024
Cardiometabolic risk factors in women: what's sauce for the goose is not sauce for the gander
Wann Jia Loh, Gerald F Watts
Current Atherosclerosis Reports
|
November 20, 2024
Inhibition of the ANGPTL3/8 Complex for the Prevention and Treatment of Atherosclerotic Cardiovascular Disease
Dick C Chan, Gerald F Watts
Current Opinion in Lipidology
|
February 19, 2024
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Dick C Chan, Gerald F Watts
Clinical Therapeutics
|
July 31, 2023
The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies
Dick C Chan, Gerald F Watts
Current Atherosclerosis Reports
|
February 26, 2025
Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?
Nick S R Lan, Gerald F Watts
The Medical Journal of Australia
|
February 5, 2013
Familial hypercholesterolaemia in Australia: new insights and developments
Ian R Hamilton-Craig, Gerald F Watts
Clinical Chemistry
|
January 8, 2021
Hypertriglyceridemia and Alzheimer Disease: Opening the Mind to New Therapeutic Opportunities
Gerald F Watts, John C L Mamo
Current Opinion in Lipidology
|
October 17, 2018
Writing on the wall for precision medicine in the prevention of atherosclerotic cardiovascular disease
Gerald F Watts, Eric S G Stroes
Page
of 71